Figure 4From: Transarterial chemoembolization plus or minus intravenous bevacizumab in the treatment of hepatocellular cancer: A pilot study Kaplan-Meier plot for progression free survival (PFS). The PFS at 16 weeks was 0.79 in the TACE-BEV arm (solid line) and 0.19 in the TACE-O arm (dashed line), with a p-value of 0.021Back to article page